ライフサイエンスコーパス: metastatic pancreatic cancer

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 on with modified FOLFIRINOX in patients with metastatic pancreatic cancer.

2 tabine in patients with locally advanced and metastatic pancreatic cancer.

3 th previously untreated, locally advanced or metastatic pancreatic cancer.

4 therapy in patients with locally advanced or metastatic pancreatic cancer.

5 atment for inoperable, locally advanced, non-metastatic pancreatic cancer.

6 t compared with gemcitabine in patients with metastatic pancreatic cancer.

7 sus gemcitabine monotherapy in patients with metastatic pancreatic cancer.

8 multicenter phase II trial in patients with metastatic pancreatic cancer.

9 cooperates with Kras(G12D) to promote highly metastatic pancreatic cancer.

10 t gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer.

11 d first-line options in locally advanced and metastatic pancreatic cancer.

12 rinotecan have similar antitumor activity in metastatic pancreatic cancer.

13 ity in patients with gemcitabine-refractory, metastatic pancreatic cancer.

14 abine/platinum regimens for the treatment of metastatic pancreatic cancer.

15 with chemotherapy-naive, locally advanced or metastatic pancreatic cancer.

16 tivity in patients with previously untreated metastatic pancreatic cancer.

17 usly untreated patients with unresectable or metastatic pancreatic cancer.

18 inotecan, and fluorouracil) in patients with metastatic pancreatic cancer.

19 e than with gemcitabine alone in advanced or metastatic pancreatic cancer.

20 proved by the FDA for gemcitabine-refractory metastatic pancreatic cancer.

21 ed and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic in

22 Five patients died of recurrent or metastatic pancreatic cancer at 60, 61, 62, 64, and 64 m

23 ults demonstrate a new strategy for treating metastatic pancreatic cancer by inhibiting cholesterol e

24 in response to NT was determined in L3.6, a metastatic pancreatic cancer cell line.

25 ne, urokinase-type plasminogen activator, in metastatic pancreatic cancer cell lines.

26 to investigate the origins and evolution of metastatic pancreatic cancer cells.

27 C16) as a novel selectin ligand expressed by metastatic pancreatic cancer cells.

28 s modified FOLFOX (mFOLFOX) in patients with metastatic pancreatic cancer for whom gemcitabine-based

29 options are now available for patients with metastatic pancreatic cancer, informed by positive resul

30 ong religious belief in a miraculous cure of metastatic pancreatic cancer is used to explore how bett

31 urred in a patient with advanced, refractory metastatic pancreatic cancer lasting 7 months.

32 livery of the nanoparticles into primary and metastatic pancreatic cancer lesions.

33 describe the generation of a progressive and metastatic pancreatic cancer mouse model after the somat

34 d metastatic breast cancer (three patients), metastatic pancreatic cancer (one patient), or cysts (on

35 therapy is mostly palliative in advanced and metastatic pancreatic cancer patients.

36 irect association of the MUC4 mucin with the metastatic pancreatic cancer phenotype and provides expe

37 Future studies in metastatic pancreatic cancer should assess the combinati

38 termine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabin

39 ion should be offered treatment per the ASCO Metastatic Pancreatic Cancer Treatment Guideline.

40 -three patients with gemcitabine-refractory, metastatic pancreatic cancer were treated continuously w

41 Thirty patients with gemcitabine-refractory metastatic pancreatic cancer were treated with capecitab

42 double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatme

43 Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chem

44 equent death of these mice from invasive and metastatic pancreatic cancer with mixed histologic chara

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。